title: Endoscopic hemorrhoidal sclerotherapy using 50% dextrose water: a preliminary report.
abstract: Injection sclerotherapy has a prominent role in the treatment of bleeding hemorrhoids. The commonly used sclerosants are not available or very expensive in Nigeria. We prospectively evaluated 50% dextrose water, used as a nonallergenic sclerosant, in the treatment of bleeding internal hemorrhoids. Forty consenting adult patients (median age 50 years [range 35-67]; 22 women) with bleeding hemorrhoids, seen over a 2-year period, were offered injection sclerotherapy with 50% dextrose water. They were assessed for response, tolerance and complications. The duration of symptoms before presentation was 3 months to 15 years. The bleeding stopped after the injection in all patients. No patient needed a repeat procedure. No complication was recorded during follow up which ranged from 2 months to 12 months. We conclude that endoscopic hemorrhoidal sclerotherapy using 50% dextrose water offers a simple, safe and effective modality of treatment if properly utilized.
authors.affiliation: Department of Anatomy and Cell Biology, Obafemi Awolowo University, Ile-Ife, Nigeria. segunalatishe@yahoo.co.uk
authors.forename: Olusegun I
authors.initials: OI
authors.lastname: Alatise
authors.forename: Olu A
authors.initials: OA
authors.lastname: Arigbabu
authors.forename: Oladejo O
authors.initials: OO
authors.lastname: Lawal
authors.forename: Abdulrasheed K
authors.initials: AK
authors.lastname: Adesunkanmi
authors.forename: Augustine E
authors.initials: AE
authors.lastname: Agbakwuru
authors.forename: Denis A
authors.initials: DA
authors.lastname: Ndububa
authors.forename: David O
authors.initials: DO
authors.lastname: Akinola
mesh_terms: D000328:Adult; D000368:Aged; D016099:Endoscopy, Gastrointestinal; D005260:Female; D005500:Follow-Up Studies; D005947:Glucose / Q000627:therapeutic use*; D006484:Hemorrhoids / Q000628:therapy*; D006801:Humans; D015552:Injections, Intralesional; D008297:Male; D008875:Middle Aged; D010149:Postoperative Pain / Q000453:epidemiology; D011183:Postoperative Complications / Q000453:epidemiology; D012597:Sclerosing Solutions / Q000627:therapeutic use*; D015911:Sclerotherapy; D016896:Treatment Outcome
chemical_list: D012597:Sclerosing Solutions; D005947:Glucose